Pharsight

Life Molecular patents expiration

1. Neuraceq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7807135 LIFE MOLECULAR Stilbene derivatives and their use for binding and imaging amyloid plaques
Mar, 2029

(5 years from now)

Drugs and Companies using FLORBETABEN F-18 ingredient

Market Authorisation Date: 19 March, 2014

Treatment: Neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

NEURACEQ family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic